CPAC Systems and Epec Enter Collaboration Agreement to Strengthen Intelligent Control System Offerings
11.6.2025 11:00:00 CEST | Business Wire | Press Release
CPAC Systems AB and Epec Oy are proud to announce a collaboration agreement rooted in a shared commitment to advancing intelligent, connected solutions in the off-highway and commercial vehicle sectors. This strategic alliance unites two leading Nordic technology companies with a common goal: to accelerate the development of scalable, integrated systems that drive innovation across the mobility landscape.
“At Epec, we are proud to join forces with CPAC Systems to deliver smarter, more sustainable control system solutions to OEMs around the world. This union is all about creating real value for our customers. By integrating our robust hardware and software platforms with CPAC Systems’ advanced system capabilities, we can accelerate the development of next-generation off-highway and commercial vehicles that are both efficient and future-ready.”
— Jyri Kylä-Kaila, CEO, Epec Oy
Combining Expertise for Next-Generation Solutions
CPAC Systems, a subsidiary of the Volvo Group, brings over two decades of experience in delivering innovative embedded systems, including autonomous vehicle platforms, electromobility solutions, and drive-by-wire technologies. Epec Oy, part of the Ponsse Group, has a strong legacy dating back to 1978 and has evolved into a leading provider of intelligent control systems, tailored electronics, and electric/hybrid vehicle technologies for the off-highway industry. With deep expertise in embedded software, connectivity, and functional safety, Epec delivers scalable solutions that support OEMs in building machines that are smarter, more efficient, and future-ready.
The collaboration agreement will enable the two companies to offer complementary solutions to OEM customers in the off-highway and commercial vehicle sectors. By aligning offerings across electronics, control systems, and system integration capabilities, CPAC Systems and Epec aim to provide customers with robust, scalable solutions, empowering operators with tools that are intuitive, intelligent, and connected.
"We are excited to collaborate with Epec to push the boundaries of intelligent control systems. Our shared ambition is to create future-ready solutions that empower OEMs to meet sustainability targets and operational demands without compromise. This alliance reflects our ongoing commitment to innovation, integration, and quality at every level."
— Marcus Wingolf, CEO, CPAC Systems AB
Shared Vision for Sustainable and Connected Mobility
Both companies share a commitment to sustainability and innovation. By leveraging their combined strengths, CPAC Systems and Epec aim to create solutions that not only meet the current demands of the industry but also pave the way for future advancements in autonomous and electric vehicle technologies.
About CPAC Systems AB
CPAC Systems AB, part of the Volvo Group, based in Gothenburg, Sweden, specializes in developing cutting-edge embedded control and automation solutions for marine, construction, agriculture, and commercial vehicle industries, focusing on areas such as electromobility, autonomous driving, and situational awareness.
www.cpacsystems.se
About Epec Oy
Epec Oy, based in Seinäjoki, Finland, is a system supplier specializing in advanced electrics and electronics for efficient, safe, and connected non-road mobile machinery and commercial vehicles. As part of the Ponsse Group, Epec has a long-standing history of providing reliable control systems and customized solutions for various applications.
www.epec.fi
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611492749/en/
Contacts
Media Contacts:
CPAC Systems AB
Email: sales@cpacsystems.se
Phone: +46 (0)31-352 16 00
Epec Oy
Email: sales@epec.fi
Phone: +358 (0)20 760 8111
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom